International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction
2024; Taylor & Francis; Linguagem: Inglês
10.1080/13506129.2024.2398446
ISSN1744-2818
AutoresSergi Yun, Giovanni Palladini, Lisa Anderson, Eve Cariou, Ronnie Wang, Franca S. Angeli, Ben Ebede, Pablo García‐Pavía,
Tópico(s)Peptidase Inhibition and Analysis
ResumoTransthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed cause of heart failure (HF).
Referência(s)